Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Imunon ( (IMNN) ) has issued an update.
Imunon, Inc. was notified by Nasdaq on November 26, 2024, about non-compliance with the minimum bid price requirement for its common stock. By June 6, 2025, Imunon managed to regain compliance with this requirement. Additionally, the company faced a delisting determination due to non-compliance with the minimum stockholders’ equity requirement but requested a hearing to appeal this decision. Recent warrant exercises have positively impacted Imunon’s stockholders’ equity, raising it to $3.0 million as of May 31, 2025.
The most recent analyst rating on (IMNN) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Imunon stock, see the IMNN Stock Forecast page.
Spark’s Take on IMNN Stock
According to Spark, TipRanks’ AI Analyst, IMNN is a Neutral.
Imunon’s financial instability, characterized by negative revenue and cash flow metrics, significantly impacts its overall stock score. Technical indicators suggest caution, with bearish trends and lack of momentum. Though the recent earnings call highlights promising clinical progress, concerns about cash runway and funding remain. Valuation metrics further reflect the stock’s risky profile, with a negative P/E ratio and no dividend yield.
To see Spark’s full report on IMNN stock, click here.
More about Imunon
Average Trading Volume: 10,595,439
Technical Sentiment Signal: Hold
Current Market Cap: $25.61M
See more data about IMNN stock on TipRanks’ Stock Analysis page.